IDIBELL

IDIBELL

Technology Transfer Office

Hospital Universitari de Bellvitge Edifici Unitat de Recerca – IDIBELL C/ Feixa Llarga, s/n 08908 L'Hospitalet de Llobregat (Barcelona) · Spain | BASIC

About IDIBELL

2 followers

The Bellvitge Biomedical Research Institute (IDIBELL) is a biomedical research center established in 2004, located in L’Hospitalet de Llobregat, south of Barcelona, Spain. Its stakeholders are Bellvitge University Hospital and Viladecans Hospital, of the Catalan Institute of Health, the Catalan Institute of Oncology, University of Barcelona and the City of L’Hospitalet de Llobregat.

IDIBELL comprises more than 1200 researchers integrated in 67 research groups strategically organized in 4 scientific areas: Cancer, Neurosciences, Translational and Regenative Medicine.

The IDIBELL Core Research Facilities include a set of centralized platforms dedicated to developing and providing research resources to assist campus biomedical researchers, such as: biobank, proteomics unit, genomics unit, cytomics unit, C. elegans facility, animal facility, statistical assessment for researchers, Clinical research unit (UICEC) and biomarkers platform. Through these different resources, IDIBELL would like to supply equipment and instrumentation, technical expertise and training to promote innovative, cutting edge research.

IDIBELL has the purpose of connecting academia and industry in order to promote innovative ideas to the market and therefore to society, by supporting professionals along the process.
Research areas
Biological SciencesMedicine, Human HealthClinical Research, TrialsPharmaceutical Products / DrugsBiology / Biotechnology and 10 more
Organization Website
Organization Type
Technology Transfer Office
Founded
2004
Headquarters
Hospital Universitari de Bellvitge
Edifici Unitat de Recerca – IDIBELL
C/ Feixa Llarga, s/n
08908 L'Hospitalet de Llobregat (Barcelona)

Publications (5)

Companion diagnostic for cutaneous and uveal melanoma. Our combination drug therapy for metastatic melanoma offers an alternative treatment for patients that do not have the BRAF V600 mutation or for patients resistant to Vemurafenib. Additionally, our technology can be used as a prognostic test to […]

Drug repurposing for lupus nephritis therapy. Compound X, already approved for human use in other medical indications, administered orally, can be repurposed for lupus nephritis treatment. The principal goal of compound X therapy in lupus nephritis is to normalize renal function or, at least, to pre[…]

✓ Non-invasive azoospermia biomarkers & Kit development ✓ High sensitivity and specificity (>90%) ✓ Effective azoospermia test in seminal plasma to avoid unnecessary biopsies.[…]

Identified miRNAs, from the semen samples, could be used as non-invasive biomarkers that contribute in the diagnosis/prognosis of malignant prostate cancer.[…]

The project, termed CardioSlice, includes: An effective in vitro tool for drug screening heart disease models A new technology for the generation of mature human cardiomyocytes[…]

Start collaborating Now!

We are currently seeking best-in-class collaboration partners for the postings listed below. You can respond to current opportunities by browsing the listed entries. We do want to invite you to cooperate with us so please contact us through the available template and we will get in contact with you. Please provide as much detailed information as possible in order to facilitate the engagement process.

Contact Person

Marta Castillejo

Marta Castillejo

Innovation Consultant at IDIBELL

View Profile

Share this site

FacebookGoogleLinkedInTwitter